Pregled bibliografske jedinice broj: 669898
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability // Journal of physiology and pharmacology, 64 (2013), 5; 597-612 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 669898 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability
Autori
Kliček, Robert ; Kolenc, Danijela ; Šuran, Jelena ; Drmić, Domagoj ; Brčić, Luka ; Aralica, Gorana ; Sever, Marko ; Holjevac, Josip ; Radić, Božo ; Turudić, Tanja ; Kokot, Antonio ; Patrlj, Leonardo ; Rucman, Rudolf ; Seiwerth, Sven ; Sikirić, Predrag
Izvornik
Journal of physiology and pharmacology (0867-5910) 64
(2013), 5;
597-612
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
colitis ; anastomosis ; cysteamine ; intestinal bowel disease ; cuprizone ; stable gastric pentadecapeptide BPC 157 ; cerebellar ataxia
Sažetak
Stable gastric pentadecapeptide BPC 157 was suggested to link inflammatory bowel disease and multiple sclerosis, and thereby, shown to equally counteract the models of both of those diseases. For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used. BPC 157 (10 μg/kg, 10 ng/kg) was applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before sacrifice) or per-orally in drinking water (0.16 μg/ml/12 ml/day till the sacrifice) while controls simultaneously received an equivolume of saline (5 ml/kg) intraperitoneally or drinking water only (12 ml/day). A multiple sclerosis suited toxic rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg intragastrically/day) was combined with BPC 157 (in drinking water 0.16 μg or 0.16 ng/ml/12 ml/day/rat + 10 μg or 10 ng/kg intragastrically/day) till the sacrifice at day 4. In general, the controls could not heal cysteamine colitis and colon-colon anastomosis. BPC 157 induced an efficient healing of both at the same time. Likewise, cuprizone-controls clearly exhibited an exaggerated and accelerated damaging process ; nerve damage appeared in various brain areas, with most prominent damage in corpus callosum, laterodorsal thalamus, nucleus reunions, anterior horn motor neurons. BPC 157-cuprizone rats had consistently less nerve damage in all damaged areas, especially in those areas that otherwise were most affected. Consistently, BPC 157 counteracted cerebellar ataxia and impaired forelimb function. Thereby, this experimental evidence advocates BPC 157 in both inflammatory bowel disease and multiple sclerosis therapy.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
108-1083570-3643 - Kvantitativna analiza i prijenos slike u patologiji (Seiwerth, Sven, MZOS ) ( CroRIS)
108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Sikirić, Predrag, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Antonio Kokot
(autor)
Sven Seiwerth
(autor)
Gorana Aralica
(autor)
Josip Holjevac
(autor)
Luka Brčić
(autor)
Robert Kliček
(autor)
Predrag Sikirić
(autor)
Danijela Kolenc
(autor)
Jelena Šuran
(autor)
Leonardo Patrlj
(autor)
Marko Sever
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE